Tenax Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TENX, updated each market day.
TENX AI Sentiment
AI sees no strong directional signal for Tenax Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Sector
Exchange
Market Cap
$257,276,290
Cap Tier
Employees
16
Headquarters
CHAPEL HILL, NC
Listed Since
Feb. 1, 1995
Website
TENX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TENX Volatility
Tenax Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
